Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
16:12:25 EDT Mon 14 Oct 2024
Enter Symbol
or Name
USA
CA



Q:XNCR - XENCOR INC - http://www.xencor.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
XNCR - Q7.021.01·21.050.221.03-0.26-1.2202.04,0722,70921.26  21.58  20.7626.84  15.3315:53:02Oct 1015 min RT 2¢

Recent Trades - Last 10 of 2709
Time ETExPriceChangeVolume
15:53:11Q20.9655-0.324553
15:53:02Q21.03-0.26100
15:53:00Q21.03-0.265
15:53:00Q21.03-0.265
15:53:00Q21.03-0.265
15:53:00Q21.03-0.265
15:53:00Q21.03-0.265
15:53:00Q21.03-0.265
15:53:00Q21.03-0.2670
15:53:00Q21.03-0.26200

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-10-10 08:09U:XNCRNews ReleaseXencor Presents Preclinical Data on XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, to be Developed for Patients with Inflammatory Bowel Diseases
2024-10-04 08:01U:XNCRNews ReleaseXencor Announces Upcoming Change to Board of Directors
2024-09-12 16:01U:XNCRNews ReleaseXencor Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
2024-09-11 06:31U:XNCRNews ReleaseXencor Announces Pricing of $175 Million Public Offering of Common Stock
2024-09-10 16:01U:XNCRNews ReleaseXencor Announces Proposed Public Offering of Common Stock
2024-09-09 07:31U:XNCRNews ReleaseXencor Announces XmAb Drug Candidates in Autoimmune Disease with Near-Term Clinical Plans and Shares Clinical Progress in Early-Stage Oncology Programs
2024-09-06 08:01U:XNCRNews ReleaseXencor to Host Research & Development Webcast and Conference Call on Monday, September 9, 2024
2024-08-05 16:01U:XNCRNews ReleaseXencor Reports Second Quarter 2024 Financial Results
2024-06-13 08:01U:XNCRNews ReleaseXencor Regains CD20 x CD3 Bispecific T-Cell Engager
2024-05-09 16:09U:XNCRNews ReleaseXencor Reports First Quarter 2024 Financial Results
2024-04-09 08:01U:XNCRNews ReleaseXencor Appoints Bart Cornelissen as Chief Financial Officer
2024-02-28 16:01U:XNCRNews ReleaseXencor to Present at Upcoming Investor Conferences
2024-02-27 16:01U:XNCRNews ReleaseXencor Reports Fourth Quarter and Full Year 2023 Financial Results
2024-02-20 16:31U:XNCRNews ReleaseXencor to Host Webcast to Review Fourth Quarter and Full Year 2023 Financial Results and Provide Vudalimab Clinical Update
2024-01-03 16:01U:XNCRNews ReleaseXencor to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2024-01-02 08:01U:XNCRNews ReleaseDane Leone Joins Xencor as Senior Vice President, Corporate Strategy
2023-11-21 16:01U:XNCRNews ReleaseXencor to Present at the Piper Sandler 35th Annual Healthcare Conference
2023-11-07 16:01U:XNCRNews ReleaseXencor Reports Third Quarter 2023 Financial Results
2023-11-07 16:01U:XNCRNews ReleaseXencor Sells Portion of Royalties and Milestones from Ultomiris ‚ ® and Monjuvi ‚ ® to OMERS Life Sciences for $215 Million
2023-11-03 12:01U:XNCRNews ReleaseXencor Presents Preclinical Data from Multiple XmAb ‚ ® Research Programs at the SITC Annual Meeting